Ehrlichia canis Vaccine Development: Challenges and Advances DOI Creative Commons
Bruna Samara Alves-Ribeiro, Raiany Borges Duarte, Zara Mariana de Assis-Silva

и другие.

Veterinary Sciences, Год журнала: 2024, Номер 11(12), С. 624 - 624

Опубликована: Дек. 5, 2024

Canine monocytic ehrlichiosis (CME) is an infectious disease caused by Ehrlichia canis, a globally recognized obligate intracellular bacterium. In addition to dogs, other animals, including humans, may be affected. Despite its epidemiological importance and impact on public health, there currently no commercial vaccine against E. canis. This study aimed present relevant aspects of the challenges advances encountered in development vaccines for CME highlight perspectives future investigations. High genetic variability, along with various evasion mechanisms employed has hindered identification antigen that targets Th1 cells immunogenic most canis isolates, considering their genotypic phenotypic characteristics. The must predominantly confer cellular humoral immunity achieve robust immune responses. Early production efforts have been challenging due low immunogenicity, difficulties establishing long-term protection, limitations techniques used. However, refinement bioinformatic tools, research this area will facilitated, thereby accelerating effective CME. According these authors, should consist multiple epitopes.

Язык: Английский

Understanding the Diagnosing of Canine Ehrlichiosis: A Comprehensive Review DOI
Monica E.T. Alcón-Chino, Salvatore G. De-Simone

IntechOpen eBooks, Год журнала: 2025, Номер unknown

Опубликована: Апрель 17, 2025

Canine Ehrlichiosis is a zoonotic disease transmitted by ticks, posing global challenge to veterinary and public health. The prevalence of canis varies across regions, emphasizing the need for comprehensive approach understanding combating this illness. This chapter explores its complex pathogenesis, highlighting how bacterium manipulates host’s immune response, leading diverse clinical manifestations. Diagnostic methods, from traditional microscopy molecular techniques serology, are critically assessed their strengths limitations. By recognizing these nuances, review equips practitioners with knowledge informed decision-making. A key focus advocating an integrated “One Health” approach, leveraging genomics, proteomics, artificial intelligence improve diagnostics develop innovative treatments globally. collaborative framework acknowledges link between human, animal, environmental health, offering holistic strategy against canine Ehrlichiosis. synthesizes scientific literature emphasizes methodological rigor, providing foundation future research interventions. With commitment principles advanced technologies, efforts can mitigate disease’s impact protect both animal human well-being.

Язык: Английский

Процитировано

0
Nonreplicating Viral Vectors for Vaccine Delivery DOI
Pankti C. Balar, Vivek P. Chavda

Опубликована: Май 23, 2025

Язык: Английский

Процитировано

0
Long-Term Protective Immunity against Ehrlichia chaffeensis Infection Induced by a Genetically Modified Live Vaccine DOI Creative Commons
Swetha Madesh, Jodi L. McGill,

Deborah C. Jaworski

и другие.

Vaccines, Год журнала: 2024, Номер 12(8), С. 903 - 903

Опубликована: Авг. 9, 2024

Human monocytic ehrlichiosis, an emerging tick-borne disease, is caused by

Язык: Английский

Процитировано

2
Ehrlichia canis Vaccine Development: Challenges and Advances DOI Creative Commons
Bruna Samara Alves-Ribeiro, Raiany Borges Duarte, Zara Mariana de Assis-Silva

и другие.

Veterinary Sciences, Год журнала: 2024, Номер 11(12), С. 624 - 624

Опубликована: Дек. 5, 2024

Canine monocytic ehrlichiosis (CME) is an infectious disease caused by Ehrlichia canis, a globally recognized obligate intracellular bacterium. In addition to dogs, other animals, including humans, may be affected. Despite its epidemiological importance and impact on public health, there currently no commercial vaccine against E. canis. This study aimed present relevant aspects of the challenges advances encountered in development vaccines for CME highlight perspectives future investigations. High genetic variability, along with various evasion mechanisms employed has hindered identification antigen that targets Th1 cells immunogenic most canis isolates, considering their genotypic phenotypic characteristics. The must predominantly confer cellular humoral immunity achieve robust immune responses. Early production efforts have been challenging due low immunogenicity, difficulties establishing long-term protection, limitations techniques used. However, refinement bioinformatic tools, research this area will facilitated, thereby accelerating effective CME. According these authors, should consist multiple epitopes.

Язык: Английский

Процитировано

0